<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80521">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057133</url>
  </required_header>
  <id_info>
    <org_study_id>15252</org_study_id>
    <secondary_id>I3Y-MC-JPBH</secondary_id>
    <nct_id>NCT02057133</nct_id>
  </id_info>
  <brief_title>A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread</brief_title>
  <official_title>A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of a study drug known as LY2835219
      in combination with different therapies (letrozole, anastrozole, tamoxifen, exemestane,
      exemestane plus everolimus, trastuzumab, or LY3023414 plus fulvestrant) for breast cancer
      that has spread to other parts of the body.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2014</start_date>
  <completion_date type="Anticipated">December 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Drug-Related Adverse Events</measure>
    <time_frame>Baseline through study completion (estimated as 12 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, and Fulvestrant</measure>
    <time_frame>Cycle 1 - Day 1: Predose through 10 hours post dose and Day 15: Predose. Cycle 2 - Day 1: Predose through 10 hours post dose. Cycles 3 to Cycle 5-Day1: Predose and immediately at end of infusion for Part F only.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Complete or Partial Tumor Response (Overall Response Rate)</measure>
    <time_frame>Baseline to study completion (estimated as 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>First dose to progressive disease or death of any cause (estimated as 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MD Anderson Symptom Inventory (MDASI) Score from Baseline</measure>
    <time_frame>Baseline, through study completion (estimated as 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the Curve (AUC) of LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, and Fulvestrant</measure>
    <time_frame>Cycle 1: Day 1 Predose through 10 hours post dose and Day 15 Predose. Cycle 2: Day 1 Predose through 10 hours post dose. Cycles 3 to Cycle 5-Day1: Predose and immediately at end of infusion for Part F only.</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>LY2835219 + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 orally every 12 hours in combination with letrozole 2.5 milligrams (mg) orally once daily in 28 day cycles. Participants may remain on treatment until discontinuation criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 + Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 orally every 12 hours in combination with anastrozole 1 mg orally once daily in 28 day cycles. Participants may remain on treatment until discontinuation criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 + Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 orally every 12 hrs in combination with tamoxifen 20 mg orally once daily in 28 day cycles. Participants may remain on treatment until discontinuation criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 + Exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 orally every 12 hours in combination with exemestane 25 mg orally once daily in 28 day cycles. Participants may remain on treatment until discontinuation criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 Dose #1 + Exemestane + Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 dose # 1 orally every 12 hours in combination with exemestane 25 mg and everolimus 5 mg orally once daily in 28 day cycles. Participants may remain on treatment until discontinuation criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 Dose #2 + Exemestane + Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 dose #2 orally every 12 hours in combination with exemestane 25 mg and everolimus 5 mg orally once daily in 28 day cycles. Participants may remain on treatment until discontinuation criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 Dose #1 + Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 dose #1 orally every 12 hours in combination with trastuzumab 6-8 mg/kg IV infusion once every 3 weeks in 21 day cycles. Participants may remain on treatment until discontinuation criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 Dose #2 + Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 dose #2 orally every 12 hours in combination with trastuzumab 6-8 mg/kg IV infusion once every 3 weeks in 21 day cycles. Participants may remain on treatment until discontinuation criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3023414 Dose #1 + LY2835219 + Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 dose # 1 orally every 12 hours in combination with LY2835219 150 mg orally every 12 hours, and fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond in 28 day cycles. Participants may remain on treatment until discontinuation criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3023414 Dose #2 + LY2835219 + Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 dose # 2 orally every 12 hours in combination with LY2835219 150 mg orally every 12 hours, and fulvestrant 500 mg IM on Day 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond in 28 day cycles. Participants may remain on treatment until discontinuation criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2835219</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 + Letrozole</arm_group_label>
    <arm_group_label>LY2835219 + Anastrozole</arm_group_label>
    <arm_group_label>LY2835219 + Tamoxifen</arm_group_label>
    <arm_group_label>LY2835219 + Exemestane</arm_group_label>
    <arm_group_label>LY2835219 Dose #1 + Exemestane + Everolimus</arm_group_label>
    <arm_group_label>LY2835219 Dose #2 + Exemestane + Everolimus</arm_group_label>
    <arm_group_label>LY2835219 Dose #1 + Trastuzumab</arm_group_label>
    <arm_group_label>LY2835219 Dose #2 + Trastuzumab</arm_group_label>
    <arm_group_label>LY3023414 Dose #1 + LY2835219 + Fulvestrant</arm_group_label>
    <arm_group_label>LY3023414 Dose #2 + LY2835219 + Fulvestrant</arm_group_label>
    <other_name>abemaciclib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 + Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 + Anastrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 + Tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 + Exemestane</arm_group_label>
    <arm_group_label>LY2835219 Dose #1 + Exemestane + Everolimus</arm_group_label>
    <arm_group_label>LY2835219 Dose #2 + Exemestane + Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 Dose #1 + Exemestane + Everolimus</arm_group_label>
    <arm_group_label>LY2835219 Dose #2 + Exemestane + Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Administered IV infusion.</description>
    <arm_group_label>LY2835219 Dose #1 + Trastuzumab</arm_group_label>
    <arm_group_label>LY2835219 Dose #2 + Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3023414</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3023414 Dose #1 + LY2835219 + Fulvestrant</arm_group_label>
    <arm_group_label>LY3023414 Dose #2 + LY2835219 + Fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Administered IM</description>
    <arm_group_label>LY3023414 Dose #1 + LY2835219 + Fulvestrant</arm_group_label>
    <arm_group_label>LY3023414 Dose #2 + LY2835219 + Fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of hormone receptor positive (HR+), human epidermal growth factor
             receptor 2 (HER2) negative metastatic breast cancer for Parts A to E, and G.

          -  For Part A (LY2835219 + letrozole): Except for ongoing therapy with letrozole, the
             participant must not have received prior systemic endocrine therapy for metastatic
             disease.

          -  For Part B (LY2835219 + anastrozole): Except for ongoing therapy with anastrozole,
             the participant must not have received prior systemic endocrine therapy for
             metastatic disease.

          -  For Part C (LY2835219 + tamoxifen): The participant may have received prior systemic
             endocrine therapy for metastatic disease and may be receiving ongoing therapy with
             tamoxifen.

          -  For Part D (LY2835219 + exemestane): The participant must have received prior
             systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor
             (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy
             with exemestane.

          -  For Part E (LY2835219 + exemestane + everolimus): The participant must have received
             prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor
             (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy
             with either exemestane or exemestane + everolimus.

          -  Have a diagnosis of HER2 positive metastatic breast cancer for Part F.

          -  For Part F (LY2835219 + trastuzumab):The participant must have received at least 1
             chemotherapy regimen for metastatic disease and may be receiving ongoing therapy with
             trastuzumab. The participant must have an estimated left ventricular ejection
             fraction within the normal range by either echocardiogram or multigated acquisition
             (MUGA) scan

          -  For Part G (abemaciclib + LY3023414 + fulvestrant): The participant may have received
             prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor
             (anastrozole, letrozole) for metastatic disease.

          -  For Parts A, B, C, D, E, and F: Have either measureable disease or nonmeasureable but
             evaluable bone disease as defined by the Response Evaluation Criteria in Solid Tumors
             (RECIST 1.1)

          -  For Part G: Have measureable disease as defined by RECIST 1.1.

          -  For all Parts except Part F: Participants must have either post-menopausal status or
             pre-menopausal status if continuing or beginning ovarian suppression with a
             luteinizing hormone-releasing hormone (LHRH) agonist such as goserelin.

          -  Have adequate organ function, including:

               -  Hematologic: Absolute neutrophil count (ANC) ≥1.5 x 10^9/liter (L), platelets ≥
                  100 x 10^9/L, and hemoglobin ≥ 8 gram/deciliter (g/dL).

               -  Hepatic: Bilirubin ≤1.5 times upper limits of normal (ULN), alanine
                  aminotransferase (ALT) ≤ 3.0 times ULN.

               -  Renal: Serum creatinine ≤ 1.5 times ULN.

          -  Have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG)
             scale.

          -  Have discontinued all previous therapies for breast cancer (including chemotherapy,
             radiotherapy, immunotherapy, and investigational therapy), except for ongoing
             corresponding combination therapy, for at least 21 days for myelosuppressive agents
             or 14 days for nonmyelosuppressive agents prior to receiving study drug(s), and
             recovered from the acute effects of therapy (until the toxicity resolves to either
             baseline or at least Grade 1) except for residual alopecia or peripheral neuropathy.
             For Part F: concurrent treatment with trastuzumab emtansine (T-DM1) is not allowed.

        Exclusion Criteria:

          -  Have metastatic breast cancer with severe organ dysfunction as assessed by symptoms
             and signs, laboratory studies, and rapid progression of the disease.

          -  Have brain metastasis without prior radiotherapy.

          -  For Parts A, B, C, D, E and G: Have received prior systemic chemotherapy for
             metastatic disease. However, the participant may have received prior systemic
             chemotherapy in the neoadjuvant or adjuvant setting.

          -  Have serious preexisting medical conditions that, in the judgment of the
             investigator, would preclude participation in this study (for example, history of
             major surgical resection involving the stomach or small bowel).

          -  Have central nervous system (CNS) metastasis and either radiotherapy or development
             of neurological changes ≤14 days prior to receiving study treatment. Participants may
             be receiving a stable dose of corticosteroids. Screening of asymptomatic participants
             without history of CNS metastasis is not required.

          -  For Part F - Cardiac disease including myocardial infarction within 6 months,
             unstable angina, or New York Heart Association (NYHA) Grade II or greater functional
             impairment.

          -  For Part G: Have type 1 diabetes mellitus or a history of gestational diabetes
             mellitus. Participants with a type 2 diabetes mellitus are eligible if adequate
             control of blood glucose level is obtained with oral therapy as documented by
             Hemoglobin A1c &lt;7%.

          -  For Part G: Have a baseline electrocardiogram (obtained from Day -14 to Day -1) with
             any of the following abnormal findings: ventricular arrhythmia, evidence of acute
             myocardial ischemia, heart block (of any degree), or QTc prolongation (defined as
             QTcB ≥450 milliseconds).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>479-587-1700</phone>
    </contact>
    <investigator>
      <last_name>Joseph Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-822-6135</phone>
    </contact>
    <investigator>
      <last_name>Teresa Helsten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-632-5869</phone>
    </contact>
    <investigator>
      <last_name>Sara Tolaney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>507-266-6264</phone>
    </contact>
    <investigator>
      <last_name>Matthew Goetz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Phys &amp; Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-305-1945</phone>
    </contact>
    <investigator>
      <last_name>Kevin Kalinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>646-888-4560</phone>
    </contact>
    <investigator>
      <last_name>Maura Dickler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-843-7714</phone>
    </contact>
    <investigator>
      <last_name>E. Claire Dees</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-271-4022</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology Hematology Care</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>506-216-8636</phone>
    </contact>
    <investigator>
      <last_name>Alison Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of Pittsburgh Cancer Inst. (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-641-3494</phone>
    </contact>
    <investigator>
      <last_name>Shannon Puhalla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>Howard Burris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-936-3524</phone>
    </contact>
    <investigator>
      <last_name>Brent Rexer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>210-593-5250</phone>
    </contact>
    <investigator>
      <last_name>Muralidhar Beeram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMO US Oncology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/breast-cancer/JPBH#?postal=</url>
    <description>Click here for more information about this study: A Study of Abemaciclib (LY2835219) in Combination With Other Therapies in Participants With Breast Cancer That Has Spread</description>
  </link>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>February 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
